Piper Jaffray’s Joshua Schimmer note that co-pay assistance programs that help patients afford expensive drugs and are used by companies like Amgen (AMGN), Biogen (BIIB), Incyte (INCY), Celgene (CELG), and Gilead Sciences (GILD) are in the news. Continue reading
Beaten-down biotechnology stocks have been so cheap for so long, rattled investors pray every day that a big drug. Continue reading
Even though 2016 got off to a rough start, the average stock in the S&P 500 is trading at about 23.8 times. Continue reading
Gilead Sciences (GILD) has been hit hard this year thanks to concerns surrounding its hepatitis-C treatments.. Continue reading
I’m pretty sure my reaction to big stock market swings is different from that of most other investors. When. Continue reading
Shares of biopharmaceutical company Gilead Sciences (GILD - Get Report) have been subject to much downward. Continue reading
Biotechnology stocks are continuing to struggle despite a brief rally in April, with major index funds such as the. Continue reading
In this segment from the Motley Fool Money radio show, Chris Hill and Jeff Fischer talk about why Gilead. Continue reading
On May 4, 2016, Gilead Sciences (GILD) was trading at a forward PE (price-to-earnings) multiple of about 6.9x.. Continue reading
Most analysts have updated their recommendations for Gilead Sciences (GILD) after the company released its 1Q16. Continue reading
